These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38293316)

  • 1. Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant
    Zhang L; Ma Y; Zhao C; Zhao S; Zhao L; Yang Y; Wang Y; Meng H; Sun J
    Infect Drug Resist; 2024; 17():239-248. PubMed ID: 38293316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
    Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
    Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
    Shi Y; Hu J; Liu P; Wang T; Wang H; Liu Y; Cao Q; Zuo X
    Infect Dis Ther; 2021 Dec; 10(4):2721-2734. PubMed ID: 34652713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
    Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
    Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
    Gu J; Xu J; Zuo TT; Chen YB
    J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
    Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
    Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Ceftazidime/Avibactam for the Treatment of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Retrospective Study.
    Lin J; Zhang L; Zhou M; Tian X; Chen J; Lu M; Liu Z
    Infect Dis Ther; 2023 Aug; 12(8):2165-2177. PubMed ID: 37653121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
    Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
    Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
    Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
    Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant
    Abu Jaber AMR; Basgut B; Hawan AA; Al Shehri AA; AlKahtani SA; Ahmed NJ; Abdi A
    Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae.
    Lima O; Sousa A; Longueira-Suárez R; Filgueira A; Taboada-Martínez C; Portela-Pino C; Nodar A; Vasallo-Vidal F; Martinez-Lamas L; Pérez-Landeiro A; Rubianes M; Pérez-Rodríguez MT
    Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1173-1182. PubMed ID: 35939239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.
    Chen W; Sun L; Guo L; Cao B; Liu Y; Zhao L; Lu B; Li B; Chen J; Wang C
    Ann Transl Med; 2020 Feb; 8(3):39. PubMed ID: 32154284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
    Chen Y; Huang HB; Peng JM; Weng L; Du B
    Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
    Kong W; Yang X; Shu Y; Li S; Song B; Yang K
    Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
    Zhuang HH; Qu Q; Long WM; Hu Q; Wu XL; Chen Y; Wan Q; Xu TT; Luo Y; Yuan HY; Lu Q; Qu J
    Infection; 2024 Jun; ():. PubMed ID: 38884857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant
    Zhang F; Zhong J; Ding H; Liao G
    Infect Drug Resist; 2021; 14():5165-5174. PubMed ID: 34908850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.
    Pu W; Fan L; Zhang Y; You D; Li M; Ma L
    Pediatr Infect Dis J; 2023 Dec; 42(12):1124-1127. PubMed ID: 37725810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.